What is Perspective Therapeutics's R&D?

Perspective Therapeutics (CATX) reported R&D of $21.37M in Q1 2026.

How has Perspective Therapeutics's R&D changed year-over-year?

Perspective Therapeutics's R&D increased by 49.1% year-over-year, from $14.33M to $21.37M.

What is the long-term trend for Perspective Therapeutics's R&D?

Over 3 years (2022 to 2025), Perspective Therapeutics's R&D has grown at a 219.5% compound annual growth rate (CAGR), from $2.58M to $84.22M.

Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.

Perspective Therapeutics CATX R&D

R&D at other companies

Eli LillyLLY

$3.51B+28.4%

CytomX TherapeuticsCTMX

$19.24M+2.0%

Monopar TherapeuticsMNPR

$3.49M+112%

ImmunomeIMNM

$46.38M+25.8%

Viridian Therapeutics, Inc.VRDN

$77.63M+1.0%

Lantheus HoldingsLNTH

$39.38M+8.4%

Other financials

Income statement

See full

Revenue$2.2M+27.3%

Gross profit$738.0K+78.3%

Operating income-$28.3M-29.5%

Net income-$26.2M-44.1%

EPS (diluted)-$0.250.0%

Balance sheet

See full

Cash & equivalents$54.0M+21.5%

Total debt$4.2M+10.9%

Total equity$347.4M+22.1%

Total assets$410.8M+24.7%

Cash flow

See full

Operating cash flow-$31.5M-45.8%

CapEx$6.9M+47.3%

Free cash flow-$38.3M-46.1%

Valuation

See full

Market cap$342.14M+33.2%

Enterprise value$292.34M+35.2%

P/S34.2×+19.6×

Profitability

See full

Gross margin33.1%-7.1pp

Operating margin-292.7%-553pp

Net margin-218.4%-781pp

FCF margin-1,073.3%—

Returns & leverage

See full

Return on equity-35.2%+2.3pp

Debt / equity0×0.0×

Current ratio8.7×-8.3×

Where this comes from

Reported directly by Perspective Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: Perspective Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Perspective Therapeutics's r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Perspective Therapeutics's R&D?: Perspective Therapeutics (CATX) reported R&D of $21.37M in Q1 2026.
How has Perspective Therapeutics's R&D changed year-over-year?: Perspective Therapeutics's R&D increased by 49.1% year-over-year, from $14.33M to $21.37M.
What is the long-term trend for Perspective Therapeutics's R&D?: Over 3 years (2022 to 2025), Perspective Therapeutics's R&D has grown at a 219.5% compound annual growth rate (CAGR), from $2.58M to $84.22M.
What does R&D mean?: Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.